Press releaseGlobe Newswire
Supernus Pharmaceuticals
SUPN · NASDAQ
$41.23+$1.39 (+3.49%)TodayMarket closed ·
Prev close $39.84
Latest news
- Press releasePRNewswire
Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders?
- Press releaseBusiness Wire
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
- Press releaseGlobe Newswire
Supernus Pharmaceuticals to Participate in September Investor Conferences
- Press releaseGlobe Newswire
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
- Press releaseBusiness Wire
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
- News
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
- Press releasePRNewswire
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders?
- Press releaseBusiness Wire
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
- Press releasePRNewswire
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?
- Press releasePRNewswire
Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
- NewsVandana Singh
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
- Press releaseBusiness Wire
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
- News
UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost Synergies
- Press releaseGlobe Newswire
Supernus Announces Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
- Press releaseGlobe Newswire
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
- Press releaseGlobe Newswire
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
- Press releaseGlobe Newswire
Supernus Pharmaceuticals to Participate in June Investor Conferences
- News
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript
- Press releaseGlobe Newswire
Supernus Announces First Quarter 2026 Financial Results
- News
Earnings Scheduled For May 5, 2026
- Press releaseBusiness Wire
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
Insights into Supernus Pharmaceuticals's Upcoming Earnings
- Press releaseGlobe Newswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
- Press releasePRNewswire
Lunai Bioworks, Inc. Issues Letter to Shareholders
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
A Preview Of Supernus Pharmaceuticals's Earnings
- News
10 Health Care Stocks Whale Activity In Today's Session
- Press releaseGlobe Newswire
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
- News
Earnings Scheduled For August 5, 2025
- Press releaseBusiness Wire
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
- Press releaseBusiness Wire
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
- NewsAvi Kapoor
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
- Press releasePRNewswire
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.
- Press releaseGlobe Newswire
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being 'Ms. Represented' in First-of-its-Kind Campaign with Supernus Pharmaceuticals
- NewsVandana Singh
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
- NewsAvi Kapoor
Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease
- NewsDavid Pinsen
Screening For Black Friday Bargains In The Stock Market
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.